Introduction that does not show symptoms is notable and needs attention. Alternatively, information from a presymptomatic individual can also occur before the onset of symptoms (i.e., during the time of incubation). Droplets (coughing or sneezing) and close contact play a central role in infection and human to human transmission. The probable asymptomatic incubation period of COVID-19 is varied from 2 to 14 days, and the mean incubation period is around five days (Lauer et al., 2020) . Hence, the symptoms may manifest in the individual from 2 days to 2 weeks after viral exposure. The SARS-CoV-2 virus has spike protein receptor binding and may use ACE2 as a functional receptor in stage 1 (Figure 2 ) for cellular entry ACE2 (Hoffmann et al., 2020) and leads to COVID-19 pathogenesis.
The SARS-CoV-2 genome consists of nucleotides nearly more than 30000 and encodes four structural proteins includes, Membrane protein, Spike protein, Envelope protein and nucleocapsid protein with several non-structural proteins. The capsid contains N-protein or nuclear capsid that binds to the single positive strand viral RNA that permits the virus to take over the human cells and convert them into viral factories. Additionally the N protein that coats the viral RNA genome plays a major role in transcription and replication. The spike protein on SARS-CoV-2 binds with ACE2 receptors on the surface of various cells mainly via the lungs causing the viral entry, where E protein's ion channel activity is found on the transmembrane region of the protein. E protein found to have a vital role in regulation and control of ion influx and efflux and thus the intracellular and extracellular environment. Hence, the ion conductivity triggered by E-protein via the manipulation of SARS-CoV-2genome may seem to be a novel route involved in pathogenesis of virus.
Ironically, ACE2, a gene mainly found in vascular endothelium in all structures such as type I and type II pneumocytes, smooth muscle cells in the pulmonary vasculature, bronchial epithelium, epithelial cells in the lungs, heart, intestine, blood vessels, testes and kidneys (Hamming et al., 2004; Imai, Dorigatti, Cori, Riley, & Ferguson, 2020) . SARS-CoV-2 (S protein) and ACE2 complex cleave S1 from S2 directly binds to the ACE2 RNA binding domain (RBD) (Figure 3 ). The ACE2 extracellular peptidase domain recognizes RBD via polar residues and facilitates viral entry through the direct plasma membrane and viral membrane fusion (Belouzard, Chu, & Whittaker, 2009) . Once entered into the host cells, Viral RNA genome translation occurs in the cytoplasm to form two structural proteins and polyproteins, that further assists the virus progeny assembly and eventually forms enveloped glycoproteins and genomic RNA within the protein machinery (Xiaowei Li, Geng, Peng, Meng, & Lu, 2020b; Perlman & Netland, 2009 ). In the cytoplasm, structured protein nucleocapsids were combined J o u r n a l P r e -p r o o f with accessory proteins, genomic RNA, and R protein in the endoplasmic reticulum, eventually release the virions through exocytosis from the infected cell (Shereen, Khan, Kazmi, Bashir, & Siddique, 2020) . The released infected viral particle readily binds with ACE2 receptors elsewhere (Z. Wu & McGoogan, 2020) and the process continues.
In response to viral and bacterial infections, the immune system develops both proinflammatory and anti-inflammatory cytokines. Following exposure to antigen-presenting cells (APCs) by SARS-CoV-2antigen, T cells release cytokines in various T cell subsets. They may further amplify the release of cytokine (cytokine storm) ( Figure 4 ) implies positive feedback between immune cells and cytokines (Kouhpayeh et al., 2020) . Alternatively, the genomic dsRNA virus may activate interferon regulatory factors and the NF-κB pathway, which releases enormous type I interferons and proinflammatory cytokines (Geng Li et al., 2020) .
The increased serum IL-6, C-reactive protein, and TNFα (P. . TNFα are likely to involve the proinflammatory condition in COVID-19 disease. The disease severity indicates the alteration in proinflammatory cytokines such as IL-7, IL-, IL-10, G-CSF, TNFα, IP-10, MIP-1A, MCP-1, in patients with COVID-19 .
Proinflammatory cytokines have been shown to encourage reactive oxygen species and the formation of free radicals that lead to oxidative stress and, ultimately, apoptosis and necrosis due to NAD+ and ATP exhaustion (Kouhpayeh et al., 2020) . Like neutrophils and macrophages, the activated phagocytes create vast quantities of reactive oxygen species and reactive nitrogen species to kill the invading agents during the inflammatory process. These intracellular sources of free radical generation may be subject to oxidative stress-induced DNA damage during viral infection (Kryston, Georgiev, Pissis, & Georgakilas, 2011) . In COVID-19 patients, oxidative stress and proinflammatory cytokines cause tissue damage mediated by inflammation. Therefore, oxidative stress and immune response deregulation result in cytokine storm, and pro-inflammation could lead to various organ dysfunctions in SARS-CoV-2 infection (C. Chen, Zhang, Ju, & He, 2020) (Table 2) .
The immune system is the multi-stage network for protecting the body against harmful bacteria, viruses, and other organisms. COVID-19's occurrence and development are mediated by viruses and the individual's immune system (Abdulamir & Hafidh, 2020) . The J o u r n a l P r e -p r o o f human self-immune system is the earliest tool to combat COVID-19. There has been little work on the relationship between SARS-CoV-2 and damage to immune cells (Table 1) . This review curiously focused on understanding the interaction between the host immune system and the COVID-19 outbreak based on accumulated data. The genetics of the immune system, e.g., HLA genes, can determine the individual infection, duration, severity, relapse, and reinfection (Xiaowei Li, Geng, Peng, Meng, & Lu, 2020a) . Also, the age factor is positively correlated with the SARS-CoV-2 viral load and clarifies the disease's severity in older patients . The aged population is prone, which could be the low immunity with higher viral load (Y. . Ironically, by resting at home (self-quarantine), the infected individuals or patients can cure themselves with acute COVID-19 infection (Cascella, Rajnik, Cuomo, Dulebohn, & Di Napoli, 2020) . It helps our immune cells to combat disease with COVID-19 and prevents transmission. The self-immune cells serve as a barrier, delay the virus's replication, and produce defensive antibodies and avoid further infections. In response to infection, the proliferation of T-cells may take a week to boost their condition. However, patients may rapidly worsen as the infected cell proliferates beyond the point where T-cells' efforts become helpless. Approximately 80% of COVID-19 patients experience a transition from mild to moderate with symptoms or no symptoms at all during this week. Yet, in the current situation to understand the immune responses is essential. Endothelium, one of the first line of the body defence system, plays a part in controlling the immune system through various receptors and cytosolic proteins (Takeuchi & Akira, 2010) . Endothelium secretes cytokines to regulate innate and adaptive immune responses, and at the site of action, it recruits immune cells (Marelli-Berg & Jarmin, 2004) . SARS-CoV-2 targets the endothelial host cell by binding its spike glycoprotein to the ACE2 receptor (Marelli-Berg & Jarmin, 2004) . SARS-CoV-2 targets the endothelial host cell by binding its spike glycoprotein to the ACE2 receptor (Lovren et al., 2008; Sardu et al., 2020) , which is highly expressed in lungs (Hamming et al., 2004) . Endothelial activation increases vascular permeability to plasma proteins, releases pro-inflammatory cytokines , tumour necrosis factor-(TNF-), chemokines, adhesion molecule (from activated leukocytes) and induces inflammation (Pober & Sessa, 2007) . The endothelial dysfunction stimulates a sequence of signalling molecules releasing nuclear factor-kB (NF-kB) to control both the innate and adaptive immune response (Oeckinghaus & Ghosh, 2009 ). If an innate immunity effort fails to abolish threat, it activates adaptive immune reactions and converts the acute inflammation into chronic inflammation (Seledtsov, Goncharov, & Seledtsova, 2015) .
Innate immune response: Innate immune responses to COVID-19, such as increased neutrophil, reduced lymphocyte, are related to infection and severity of disease and eventually J o u r n a l P r e -p r o o f contribute to the death of patients (F. Wu, Zhao, & Yu, 2020; P. Zhou et al., 2020) . Probably the leading cause of the life-threatening respiratory situation in COVID-19 patients is due to the secretions of granulocytes, and proinflammatory macrophages that damage cells and induce innate inflammation in the lungs (Z. . The lower frequency of recruitment of monocytes (CD16+CD14 +) in the COVID-19 patient's blood, shows the infection (Thevarajan et al., 2020) ,with no difference in frequency of NK (natural killer) cell (Thevarajan et al., 2020) . Effective innate immune responses to control the viral replication against viral infection depend on the Interferon-(IFN-) and Toll-like receptors 3 (TLR3) expressions (Kawai & Akira, 2006) . Endothelium chiefly expresses both IFN-and TLR3 (Tissari, Sirén, Meri, Julkunen, & Matikainen, 2005) and TLR9 against virus and bacteria (El Kebir, József, Pan, Wang, & Filep, 2009 ). Hence, highly efficient innate immune responses in young children could be a reasonable explanations for less severe SARS-CoV-2 infection (Kelvin & Halperin, 2020) . These facts indicate strongly that the innate immune response may act as a vital factor for the outcome of a disease.
developing autoimmunity or anti-inflammation (Cecere, Todd, & LeRoith, 2012) . CD4+ T cells specifically stimulate the production of virus-specific antibodies and the activation of Tdependent B cells (Xiaofeng Li et al., 2006) . CD8+ T cells are directly cytotoxic to the virally infected cells (Doherty et al., 1997) . However, the expression and survival of CD4+ T cells and CD8 + memory T cells depend on endothelium (Shiao, McNiff, & Pober, 2005) . Among SARS-CoV-2 -infected patients, the number of CD4 + T cells and CD8+T cells in the blood has been substantially decreased, showing evidence of excessive activation with elevated levels of HLA-DR (Z. . Moreover, increased concentration of proinflammatory substances in CD4+ T cells and cytotoxic granules in CD8+ T cells account for severe immune insults in this patient (Z. .
Multi-factorial immune responses such as increased antibody-secreting cells, helper T cells, activated CD4+ T and CD8+ T cells, IgM, and IgG antibodies were detected non-severe COVID-19 recovered patient's blood (Thevarajan et al., 2020) . Contrary to this, IgM & IgG antibodies were simultaneously increased on day 10th following the onset of symptoms in 23 patients with COVID-19 and this may clarify the neutralising activity of the antibodies with the surface spike receptor-binding domain of SARS-CoV-2 virus (Y. . The vulnerable SARS-CoV-2 nduces hardly any chronic symptoms after incubation and provokes protective immune responses. During the incubation period, the body develops multiple approaches to improve immune responses. The successful eradication of the SARS-CoV-2 consequences relies on the infected individual health status and antigen loci of major-J o u r n a l P r e -p r o o f histocompatibility complex (HLA) (X. Li et al., 2020b) . In case the infected personal general health and HLA haplotype (which elicits specific antiviral immunity) are unable to cope with the viral infections he/she may enter a severe stage and encounter the intense detrimental inflammatory response, especially in the lung (X. Li et al., 2020b) . Henceforth more detailed understanding of both the innate and adaptive immune responses to SARS-CoV-2 is now essential to understanding its pathogenesis.
Like the SARS coronavirus, COVID-19 patients usually develop upper respiratory tract illness (T. Wang et al., 2020) (Table 1 ). The ACE2 receptors markedly expressed in epithelial cells of the nasal cavity, type2 alveolar cells of lungs (Abassi, Skorecki, Heyman, Kinaneh, & Armaly, 2020), as well as heart, liver, kidney and gastrointestinal tract. In which lungs with the larger surface are more susceptible to COVID -19. Viral S protein on SARS-CoV-2 additionally requires various cofactors, especially TMPRSS2, found to be located in alveolar pneumocytes and responsible for SARS-CoV-2 entry and infection during interaction with host cell surfaces (Lukassen et al., 2020) . Notably, two proteases ADAM17 and TMPRSS2 decide the fate of ACE 2 influence on organs along with the SARS-CoV-2 towards multiorgan failure and viral pathogenesis (Heurich et al., 2014; Xiao, Sakagami, & Miwa, 2020) . The ventilatory ratio, a bedside index of lung dead space, and ventilation efficiency, is found to be increased in COVID-19 patients (X. Liu et al., 2020) . The major consequences and reason for life threatening are respiratory disorders at severe stages is also due to the hyperinflammation associated with the increase in proinflammatory cytokines and depressed innate immunity (Z. .
Patients with chronic obstructive pulmonary disease (COPD) are known to have increased expression of ACE2 receptors leads to severe lung diseases (Guoping Li et al., 2020) with chronic inflammation and pyroptosis (Tian et al., 2020) . The expression of ACE2 was not substantially different and does not indicate any difference in the susceptibility to COVID-19 infection among normal individuals and COPD asthma patients. However, persons with underlying lung disorders may be at higher risk for severe chronic airway disease or death (Guoping Li et al., 2020) . The exact mechanism and molecular interaction (including the various other proteins and cofactors) need to be focused during the interaction of SARS-CoV-2 with the lungs.
J o u r n a l P r e -p r o o f However, COVID-19 has reported significantly causing heart failure and death to persons with no signs of respiratory distress, regardless of harmful pre-cardiovascular disease (Madjid, Safavi-Naeini, Solomon, & Vardeny, 2020) . SARS-CoV-2 induces direct insult to myocardial cells and their dysfunction (Clerkin et al., 2020; Zheng, Ma, Zhang, & Xie, 2020) (Table 1 ). In Wuhan, China, 52 patients (27.8%) out of 187 patients had the history of myocardial injury with elevated Troponin T (T. Guo et al., 2020) and six patients (15%) out of 41 patients had cardiovascular illnesses . The level of plasma Troponin demonstrates a significant linear correlation for the levels of C-reactive protein and N-terminal pro-brain natriuretic peptide. In early and rapid diagnosis, cardiac Troponins can play an additional role in managing and categorizing the significant risk in cardiac patients and deciding on their emergency or surgical intervention care (Rajappa & Sharma, 2005) . In COVID-19 patients, cardiovascular markers such as Creatine kinase, Creatinine, Troponin I (cardiac), Brain Natriuretic Peptide, Lactate dehydrogenase, along with Alanine aminotransferase, Aspartate aminotransferase, and D-dimer concentration were markedly elevated (T. .
Myocardial injury in COVID-19 may also result from cardiac dysfunction and arrhythmias (T. Guo et al., 2020) . As compared to lungs, the heart is the second major organ reported to get highly affected by SARS-CoV-2 entry via SARS-CoV-2 spike protein with ACE2, widely expressed in the heart and lungs (Zou et al., 2020) . SARS-CoV-2 invades myocardial cells in the heart through ACE2, probably through pericytes resulting in increased macrophage infiltration, capillary endothelial cell dysfunction, and decreased ACE2 expression. The persistent increase in inflammatory cytokines following infection with COVID-19 may eventually lead to a reduction in coronary blood flow, oxygen supply, microthrombogenesis, and degradation of the coronary plaque (T. Guo et al., 2020) pays the way to myocardial injury and failure. Cytokine storms and hyper inflammation will further aggravate the above responses (Akhmerov & Marban, 2020).
The severity of the COVID -19 outbreak is attributed primarily to viral spike protein interaction with host cells through ACE2 receptors that are highly expressed in the heart and lungs (P. . Concerning viral load and subsequent incubation period (4-14 days), COVID-19 results in mild to severe symptoms associated with respiratory distress and heart failure (Lauer et al., 2020) . SARS-CoV-2 once targets with ACE2, might elevates the production of angiotensin II level through the action of NADPH oxidase activity (Rukavina Mikusic et al., 2014) ; and may lead to endothelial dysnfunction along with chronic myocardial hypoxia.
Cytokine storm and nitric oxide (NO: The effect of COVID-19 on the cardiovascular system could be further enhanced by an ACE2 deficiency correlating with reduced bioavailability of J o u r n a l P r e -p r o o f nitric oxide and an eNOS expression in the aorta (Rabelo et al., 2016) to control homeostasis of blood pressure and vascular injury. The elevated angiotensin II that stimulates the production of cGMP degrading phosphodiesterases results in decreased bioavailability of cGMP and cause vascular dysfunction and injury (Stegbauer et al., 2013) . However, the SARS-CoV-2 contribution and percentage towards myocardial injury via direct viral invasion or indirect systemic toxicity to multiple organs remains indistinct irrespective of the morbidity.
Therefore the harmful effects of COVID-19 on the heart will be mediated by SARS-CoV-2 viral load after its entry through the lungs (primary route). However, the COVID-19 manifestation on the myocardial damage and cardiovascular homeostasis either directly or indirectly remains elusive regardless of the morbidity.
Liver, a large metabolic organ that is continuously exposed to dietary antigens, viruses and has recently reported to have varying degrees of damage in patients with COVID-19 (Table 1) With an Increases in Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST), followed by slightly elevated levels of bilirubin with or without mechanical ventilation (Gu, Han, & Wang, 2020; Zhang, Shi, & Wang, 2020; G. Zhang et al., 2020) . ). In COVID-19 patients, it is unclear whether the liver damage is caused by viral manifestations in liver cells or by the induced medication. ACE2 receptor in the target cell is the key binding site for SARS-CoV-2 virus, but the only medium expression of ACE2 in the liver is confirmed(M.-Y. Li, Li, Zhang, & Wang, 2020) ); however, bile duct cells (cholangiocytes) have highly enriched ACE2 receptors, which may support viral binding and derangements of liver function (Chai et al., 2020; Hoffmann et al., 2020) .
In contrast, immune responses to viral infection triggered by either immune interference or collateral damage to cytotoxic T cells and Kupffer cells in the liver may cause liver damage with no viral load (Bangash, Patel, & Parekh, 2020) . Non-specific inflammatory markers such as elevated neutrophil and neutrophil to lymphocyte counts (virus-induced cytokine storm), coagulation and fibrinolysis pathway activation in response to sustained inflammation, high levels of ferritin reflect the involvement of hepatic cells (Bai et al., 2020) (Table 1) . Also, a phenomenon called 'bystander hepatitis' that raises transaminases (AST and ALT) and J o u r n a l P r e -p r o o f circulatory cytokines may imply general immune stimulation or inflammation in systemic viral infections without compromising the function of the liver (Boettler et al., 2020) (Table 1) .
Uncertainly, COVID-19 infected patients with hepatotoxicity or liver injury may be due to antibiotics, antivirals and steroid medicines (Xu, Liu, Lu, Yang, & Zheng, 2020) .
We consistently indicate that liver injury in COVID-19 may be the direct insult to the liver or bile cells via receptors of ACE2. It is further aided by hyper inflammation, cytokine storm or bystander hepatitis and drug-induced damage. In COVID-19 diagnosis and management, patients already with comorbidities such as liver damage are recommended to treat with hepatoprotective medicines for better progress and outcome. We required further research to elucidate the effect of COVID-19 on the liver.
A recent study of COVID-19 on kidney dysfunction (Table 1) High levels of IL-6 in cytokine release syndrome may cause kidney damage. Possibly other various strategies towards kidney injury could be organ (Lung-kidney) crosstalk; inflammatory reactions and substances subsequently released lung damages could harm the kidney.
Alternatively, kidney epithelial cell injury also caused severe lung damage and other organs (Ronco & Reis, 2020) . COVID-19 patients with acute kidney injury had higher mortality risk (5.3 times) than those without acute kidney injury, and chronic disease patients had moderate mortality risk (1.5 times) (Z. Li et al., 2020b) . Therefore, monitoring the functions of the kidneys in COVID-19 patients regardless of chronic comorbid disease is equally important to reduce the risk of mortality and for improved outcomes. Patients need personalized medicine and J o u r n a l P r e -p r o o f differential management from the clinicians irrespective of the conditions; therefore, an indepth understanding of cardiopulmonary physiological interactions in COVID-19 patients is crucial for effective management.
We have précised concepts that link the pathogenesis of kidney dysfunction in COVID-19 infection. Renal tubular epithelial cells, organ crosstalk, and cytokine storm are the existing possible potential involvement in kidney damage and are strongly interrelated. It is hoped that baseline existing understanding will lead to earlier diagnosis, recognition, and treatment in the future to improve the outcomes of COVID-19 patients.
Reports of 'Neuro-COVID-19 units show a common occurrence of neurological symptoms in COVID-19 patients (Talan, 2020) (Table 1) . Symptoms of brain dysfunction such as headache, distressed consciousness develop in 40 % of patients with COVID-19 (Mao et al., 2020) .
SARS-CoV-2 in cerebrospinal fluid of infected patients suggests viral encephalitis (Cai et al., 2020) . In a few patients, even with neurologic symptoms, develop symptoms associated with COVID-19 (Mao et al., 2020) .
The olfactory dysfunction such as loss of taste or smell among COVID-19 patients suggests that viruses infect the olfactory neuron (Giacomelli et al., 2020; W.M, 2020.) Bain invasion through an ACE2 receptors : ACE2 is identified as the acting receptor for SARS-CoV-2, and present in multiple human organs, including the nervous system (Hamming et al., 2004) . The detection of ACE2 receptors over glial cells and other neurons, making them a potential target for SARS-CoV-2 (Baig, Khaleeq, Ali, & Syeda, 2020) and this can also disrupt the blood-brain barrier by disrupting the vascular system and reaching the CNS.
COVID-19 can potentially damage the capillary endothelium within the brain and contribute to elevated blood pressure. The risk of SARS-CoV-2 cerebral haemorrhage through an ACE2 receptor can result in abnormally high blood pressure and increase cerebral haemorrhage (Y. . Therefore, it is too recent to generate statistical evidence, and epidemiology of COVID-19 concerning CNS remains to be learned. Muscle relaxation has a positive effect on improving sleep quality and reducing anxiety (Polak et al., 1998) . The widespread deregulated cellular homeostasis of COVID-19 patients caused by pulmonary, renal, cardiac, and circulatory damage could complicate and manifest into various neurological complications yet to be learned.
The extrapulmonary manifestation of COVIDd-19 unfolds the symptoms of disease in digestive system. Includes nausea, vomiting, diarrhoea, abdominal pain and other nonspecific GI illness (Cipriano, Ruberti, & Giacalone, 2020; Gu et al., 2020; J o u r n a l P r e -p r o o f (Table 1 ). The finding of SARS-CoV-2 RNA in the stool sample, has gained much attention from clinicians and researchers towards GI inspection, symptoms and analysis (A. Tang et al., 2020; F. Xiao et al., 2020) (Table 1 ). In cancer patients COVID-19 was reported to have a higher risk (Liang et al., 2020) .
Laboratory report of COVID-19 patients with digestive symptoms showed higher liver enzymes, decreased monocytes, prolonged prothrombin time, and received additional antimicrobial management than patients with no digestive symptoms(Pan et al., 2020).
Interestingly, the presence of a virus among patients with confirmed SARS-CoV-2 is recorded in stool samples , from anal and rectal swabs (Holshue et al., 2020; Young et al., 2020) even after the clearance of virus in the respiratory tract (Cipriano et al., 2020) . It was also persistently positive on rectal swabs in 8 out of 10 paediatric patients, even after negative nasopharyngeal swabs tests (Y. . Tang et al., 2020) . Based on the above evidence, initial gastrointestinal symptoms in COVID-19 patient needs attention and notable. As it is highly involved in the community spreading and transmission, SARS-CoV-2 influence on GIT must be incorporated in early screening, detection, awareness, diagnosis, safety precautions, patient isolation, and early non-invasive diagnostic tool as much as respiratory symptoms are given importance. The extrapulmonary presentation of COVID-19 manifests the signs of illness within the digestive system, includes nausea, vomiting, diarrhoea, stomach pain and other nonspecific GI disorders (Cipriano, Ruberti, & Giacalone, 2020; Gu et al . , 2020; (Table 1) .
In COVID-19 cases, sepsis is one of the most expected outcomes (F. , suggesting RBC involvement in COVID-19 infection (Lippi & Plebani, 2020) . (Abrahams, 2020; N. Chen et al., 2020; Menk et al., 2018; (Table 1) . Bioinformatics analysis has found that SARS-CoV-2 glycoproteins such as orf1ab, orf10, and orf3a attacks 1beta chain of haemoglobin open reading frame 8 (ORF8) that binds to the porphyrin of haem and displaces iron (Wenzhong & Hualan, 2020) . In general, SARS-CoV-2 may not be considered to be the first known virus to alter porphyrin metabolism; hepatitis C virus (Hep C) and human immunodeficiency virus (HIV) infection also contribute to a non-acute form of porphyria (Wenzhong & Hualan, 2020) .
Porphyria is the disorder related with heme biosynthesis pathway and loss of autonomic control of breathing and autonomic neuropathy is a clinical feature of acute porphyria (Tracy & Dyck, 2014) .
Report on the relation between the ABO blood group and SARS-CoV-2 susceptibility to increased risk of COVID-19 infection among people with blood group A relative to other blood group (Zhao et al., 2020) . In patients affected by COVID-19, haemostatic abnormalities such as disseminated intravascular coagulation and pulmonary embolism have been reported Le Berre, Marteau, Emmerich, & Zins, 2020; Tang, Li, Wang, & Sun, 2020) . Most haemostatic abnormalities may occur due to increased D-dimer (Lippi & Favaloro, 2020) , thrombocytopenia (R. S. Wong et al., 2003) , prolonged prothrombin time (Le Berre et al., 2020) , thrombin time , elevated fibrin/fibrinogen degradation products and decreased activated partial thromboplastin time .
Hence, depending on the available reports, we have speculated that the primary pathogenic mechanism of COVID-19 does not only confide with lung. However, sepsis, acute porphyria, disseminated intravascular coagulation, and interaction of SARS-CoV-2 surface glycoprotein with 1-beta chain of haemoglobin (Wenzhong & Hualan, 2020) , is often the secondary complications observed in COVID-19 patients.
This review concluded ( Figure 5 ) that SARS-CoV-2 is intervened mainly through ACE2 receptor and other cofactors, mainly TMPRSS2 in the lung and further progress to pneumonia and ARDS. However, depending on viral load and regulated by the ACE2 receptor, an infection may further spread to other organs such as heart, liver, kidney, Brain, endothelium, GIT, immune cell, and RBC thromboembolism. This may follow with cytokine storm with an extensive discharge of proinflammatory cytokines from deregulating the immune system. This overall cytokine results in systemic inflammation and organ crosstalk resulting in multiorgan failure (Table 2 ). This finding may lead the clinician and scientist to the diverse approach to fight with COVID-19. More attention and studies are required to understand the involvement The newly developed genomic RNA, nucleocapsid, and enveloped glycoproteins assembled via endoplasmic reticulum and golgi complex to form viral particle buds. Finally, the vesicle that contains the virion fuses with the plasma membrane, resulting in viral release through exocytosis. The newly developed genomic RNA, nucleocapsid, and enveloped glycoproteins assembled via endoplasmic reticulum and golgi complex to form viral particle buds. Finally, the vesicle that contains the virion fuses with the plasma membrane, resulting in viral release through exocytosis. 
Case report To find the pathology of a COVID -19 patient died with acute respiratory syndrome (ARDS). (by obtaining biopsy samples at autopsy)
CD4 T cells as well as CD8 T cells were activated (as indicated by high HLA-DR) although they had significantly less count. There was also a high level of proinflammatory factor in CD4 T cells, and a high level of cytotoxic granules in CD8 T cells. 
To brief molecular improvement in immune pathology in COVID-19 based on infections with SARS-CoV and MERS-CoV.
The immune system influences of the person include human leukocyte antigen (HLA genes), when a person is infected with SARS-CoV-2 virus, prolongation and serious form of the disease, and reinfection.
(X. Li et al., 2020a) Editorial
To Observe immunological response of COVID-19-infected patient.
Multi-factorial immune responses with high levels of antibody-secreting cells (IgM and IgG antibodies) and CD4 T cells and CD8 T cells with more activation Up to recovery in the blood. 
Anti-inflammatory approaches against pro-inflammatory cytokines (IL-1 and IL-6) and COVID-19caused lung inflammation.
. IL-37 and IL-38 function as potential therapeutic cytokines which inhibit pro-inflammatory cytokine release.
. Research article Renin-angiotensin system inhibitors may be a safe alternative for COVID-19 pneumonia therapy
In COVID-19 patients with pneumonia, angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists inhibitors may reduce inflammatory response and mortality in the pulmonary system.
(M. Sun, Yang, Sun, & Su, 2020) Case study
Serial computed tomography finding in COVID-19 pneumonia Progress in both lungs with peripheral consolidations and ground-glass opacities. The lesions were removed after treatment leaving the fibrous lesions behind. (Wei et al., 2020) Research article The risk of severe increases with angiotensin-converting enzyme inhibitors and angiotensin blockers
Increases the receptors of ACE2, and acts as binding sites in the lungs for SARS-CoV-2 virions. (Diaz, 2020) Research article ACE-2 Expression in Small Airway Epithelia of smokers and COPD Patients: Implications for SARS-CoV-2 Expression of ACE-2 in Small Airway Epithelia of Smokers' and COPD Patients': Implications for COVID-19
In COPD patients and smokers the expression of ACE-2 in small epithelial cells of the airway has increased. ACE -2 is the SARS-CoV-2 entry receptor that contributes to serious infections. (Leung et al., 2020) Research article COVID-19 pathogenesis from a perspective of cell biology
The magnitude of COVID-19 can be understood by portion of the infected lung. Gas exchange section of the lung was involved in moderate infection, bringing airways and serious infection. (Mason , 2020) Review Neuroinvasive ability of COVID-19 in respiratory failure.
The Brain glial cells and neurons express ACE2, making them simple target for COVID-19.
(Baig et al., 2020)
Review Pathophysiology of COVID19 and its impact on cardiovascular system 
To detect positive patients with GI manifestations and faecaloral transmission in COVID-19.
The emphasis would be on the initial manifestations of COVID-19 digestive symptoms that would assist in early identification, diagnosis, early isolation, and rapid response. Research article To examine the prevalence and outcomes of Gastrointestinal symptoms in patients with cancer who are COVID-19 positive.
Digestive symptoms such as diarrhoea are usually seen in COVID-19 cancer patients and early increase in suspicion index should be considered in at-risk patients. (Liang et al., 2020) 